Vol 15, No 2 (2019)
Date published: 2019-05-17
Table of Contents
open access
paid access
Beata Hryciuk, Bartosz Szymanowski, Michał Bieńkowski, Adrian Perdyan, Aleksandra Korwat, Kamil Winnik, Barbara Radecka, Jolanta Żok, Natalia Cichowska, Katarzyna Sosińska-Mielcarek, Rafał Pęksa, Renata Duchnowska
Critical appraisal of clinical trials in oncology — part I
Marcin Kaczor, Rafał Wójcik, Joanna Połowinczak-Przybyłek, Piotr Potemski
Benefits and difficulties during brain radiotherapy planning with hippocampus sparing
Monika Konopka-Filippow, Ewa Sierko, Marek Z. Wojtukiewicz
Neratinib in adjuvant treatment of patients with HER2-positive breast cancer — less is more?
Ewa Cedrych, Ida Cedrych
Why do we need a new BRAF-MEK inhibitor combination in melanoma?
Katarzyna Kozak, Piotr Rutkowski
Małgorzata Flis, Paweł Krawczyk, Izabella Drogoń, Katarzyna Kurek, Robert Kieszko, Janusz Milanowski
Nivolumab in the treatment of advanced renal cell carcinoma
Piotr Tomczak, Zuzanna Synowiec
Aneta Lebiedzińska, Dawid Sigorski, Maciej Michalak, Zygmunt Kozielec, Anna Doboszyńska, Dariusz Zadrożny, Paweł Różanowski
When to say “no” to a patient with an ovarian tumour and in poor general condition?
Kamila Kaźmierczak, Joanna Kufel-Grabowska, Tomasz Kozłowski, Błażej Nowakowski